NICE have issued a positive Final Evaluation Document (FED) for Volanesorsen for the treatment of FCS for routine care on the NHS in England.

"Volanesorsen is recommended as an option for treating familial chylomicronaemia syndrome in adults with genetically confirmed familial chylomicronaemia syndrome who are at high risk of pancreatitis, and when response to diet and triglyceride- lowering therapy has been inadequate." The medicine is to be used in line with the marketing authorisation "as an adjunct to diet".

Read the NICE decision here